SynthesisInternational journal of molecular sciences2026
Is Cold Atmospheric Plasma Selective for Breast Tumor Cells? A Systematic Review.
Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer (BC) is the most diagnosed cancer among women and ranks as the fourth leading cause of cancer-related deaths worldwide. Current main treatments have significant issues, including a lack of selectivity for tumor cells. Over the past decade, cold atmospheric plasma (CAP) has been examined as possible therapy for cancer. Therefore, this systematic review aimed to understand if there is selectivity of CAP or plasma-activated solutions (PAS) for BC cell lines in vitro. The research in PubMed, Embase, Web of Science, and Cochrane databases resulted in 243 articles, and of these, 32 in vitro studies were included. MDA-MB-231 and MCF-10A cells were the most used. MTT, MTS, SRB, trypan blue, clonogenic, resazurin, luciferin, annexin-V/propidium iodide, reactive oxygen species (ROS), and scratch assays were carried out. This research showed that CAP and PAS tended to reduce the viability of cancer cells, causing less damage to nonmalignant cells, demonstrating selective or partial selectivity toward cancer cells. One of the mechanisms potentially underlying this selectivity is the elevated ROS basal levels typically found in cancer cells. These high ROS levels may lead to increased expression of membrane aquaporins and a reduced capacity for antioxidant defense, contributing to heightened membrane permeability and vulnerability to oxidative damage. Additionally, the treatments also tended to reduce the migration of BC cells. CAP treatment enhanced several other therapies' effectiveness. However, the differences in experimental protocols, treatment approaches, equipment features, and exposure times observed across the studies made it impossible to carry out the planned meta-analysis. Existing in vitro evidence indicates that CAP/PAS exhibit partial selectivity for breast cancer cells, but due to the heterogeneity in experimental protocols, the consistency of selectivity remains to be verified. Further research is needed to elucidate their mechanisms of action and to standardize experimental methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.